UAE Stomach Cancer Treatment Market By Treatment Type (Standard Chemotherapy, Targeted Therapy, and Immunotherapy), By Disease Indication (Gastric cancer/Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumours), By Route Of Administration (Oral and Injectable), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR Antagonists, and Others), By Region, Competition, Forecast and Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 8.85 Million
CAGR (2026-2031)	17.92%
Fastest Growing Segment	Standard Chemotherapy
Largest Market	Dubai
Market Size (2031)	USD 23.79 Million

Market Overview

The UAE Stomach Cancer Treatment Market will grow from USD 8.85 Million in 2025 to USD 23.79 Million by 2031 at a 17.92% CAGR. The UAE Stomach Cancer Treatment Market encompasses a range of medical interventions designed to address malignancies originating in the stomach's lining, including surgical resections, radiation therapy, chemotherapy, targeted therapies, and immunotherapies, often complemented by palliative care. This market experiences robust growth primarily driven by the increasing incidence of cancer within the UAE, notably influenced by evolving lifestyle factors such as dietary changes and an aging populace. According to the UAE Ministry of Health and Prevention, in 2023, 7,487 new incidents of cancer were recorded, highlighting a rising demand for oncology services. Additionally, substantial investments in healthcare infrastructure and continuous advancements in medical technology further support market expansion.

These advancements include sophisticated diagnostic tools and the introduction of innovative treatment modalities that enhance patient outcomes. However, a significant impediment to market growth remains the high cost associated with advanced stomach cancer treatments. This financial burden can present a considerable barrier to access for numerous individuals, particularly those with limited or inadequate insurance coverage.

Key Market Drivers

Rising Incidence Drives Demand for Diagnostics and Treatment
The rising incidence of stomach cancer is a significant driver for the UAE Stomach Cancer Treatment Market. This increase directly increases the demand for comprehensive diagnostic services and therapeutic interventions. According to The National, June 2025, new cancer cases in the UAE collectively rose by 60 percent between 2019 and 2023, reflecting a growing patient pool requiring oncology care. Factors such as evolving lifestyle patterns, including dietary changes and an aging population, contribute to this trend, which necessitates a robust healthcare response.

Technological Innovation and Expanded Access
Advancements in diagnostic and treatment technologies are another substantial driver for the market. Continuous innovation introduces more precise diagnostic tools and effective therapeutic modalities, improving patient outcomes. In June 2025, the Dubai Health Authority granted initial approval to Yas Healthcare for establishing the UAE's first proton therapy center in Dubai, a highly advanced form of radiation therapy designed for exceptional accuracy in tumor targeting. Such technological strides attract specialized medical expertise and draw patients seeking advanced care within the region. Furthermore, the expanding healthcare access underpins market growth; according to the Dubai Health Authority, in 2025, the number of beneficiaries covered under Dubai's health insurance system exceeded 4.9 million.

Download Free Sample Report

Key Market Challenges

Financial barriers restrict patient access to stomach cancer care
A significant impediment to the growth of the UAE Stomach Cancer Treatment Market is the high cost associated with advanced therapeutic interventions. These substantial expenses generate a considerable financial burden for patients and their families, particularly for individuals with limited or inadequate insurance coverage. This financial barrier directly restricts patient access to essential stomach cancer care.

Economic burden constrains market growth
The high financial outlay for state-of-the-art surgical resections, targeted therapies, immunotherapies, and prolonged chemotherapy regimens directly limits the number of individuals who can pursue or complete optimal treatment pathways. According to Professor Humaid Al Shamsi, head of the Emirates Oncology Society, in 2025, cancer imposes an economic impact of approximately Dh39.9 billion annually on the UAE, encompassing treatment and lost productivity. This significant economic burden, often passed to patients through co-payments and uncovered services, compels some to forgo or delay optimal treatment. Consequently, the market's expansion is constrained as the economic barrier limits the effective demand for available treatment modalities, despite the clinical need.

Key Market Trends

Precision Oncology and Immunotherapy in UAE Stomach Cancer Care
The accelerated integration of targeted therapy and immunotherapy is significantly reshaping the UAE stomach cancer treatment landscape. These modalities offer highly specific interventions, either targeting cancer cells directly or leveraging the body's immune system, marking a shift from traditional systemic chemotherapy. This precision approach improves efficacy and reduces side effects. Growing adoption drives demand for advanced molecular diagnostics and fosters collaborations among pharmaceutical companies and healthcare providers. According to The National, September 2025, in the 'UAE Health Sector Sees Significant Investment in Personalized Cancer Care', an estimated AED 100 million has been allocated to developing personalized medicine infrastructure and programs across oncology centers in the UAE over the past year. This trend underscores a strategic move towards individualized treatment protocols.

Expansion of Minimally Invasive and Robotic Surgery in UAE Stomach Cancer Care
The expansion of minimally invasive and robotic surgical interventions represents another pivotal trend influencing the UAE stomach cancer treatment market. These advanced surgical techniques, including laparoscopic and robotic-assisted procedures, offer smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery. This enhances patient experience and outcomes, increasing preference for such methods. Investment in specialized surgical equipment and training for oncology surgeons is growing to meet this demand. According to Gulf News, March 2026, in the 'Leading Hospital Group Expands Robotic Surgery Capabilities in UAE', a prominent healthcare provider announced the deployment of six new state-of-the-art robotic surgical systems across its facilities in Dubai and Abu Dhabi. This highlights increasing infrastructure development for advanced surgical care.

Segmental Insights

Standard Chemotherapy: Fastest-Growing Segment Driven by Efficacy and Expanded Access
In the UAE Stomach Cancer Treatment Market, Standard Chemotherapy stands out as the fastest-growing segment. This rapid expansion is primarily driven by chemotherapy's established efficacy as a foundational cancer treatment, remaining a crucial component in comprehensive oncology protocols. Increased cancer awareness and enhanced diagnostic capabilities across the UAE contribute to more patients being identified and starting treatment, for which chemotherapy is a widely accessible option. Furthermore, governmental efforts, exemplified by initiatives from bodies such as the Dubai Health Authority, focus on improving overall cancer care and ensuring access to diverse treatment modalities, including chemotherapy, thereby supporting its sustained demand and integration into multidisciplinary treatment plans.

Regional Insights

Dubai leads UAE stomach cancer treatment through robust healthcare infrastructure, advanced therapies, and supportive policy initiatives.
Dubai leads the UAE Stomach Cancer Treatment Market due to its robust healthcare infrastructure and commitment to medical innovation. The emirate serves as a prominent healthcare hub, featuring world-class hospitals and specialized oncology centers offering advanced therapies such as precision medicine, immunotherapy, targeted therapy, and advanced radiation techniques. This dominance is further supported by the Dubai Health Authority's strategic initiatives aimed at expanding access to comprehensive cancer care and fostering a favorable regulatory environment for pharmaceutical advancements. Dubai's focus on attracting leading medical professionals and its emergence as a regional destination for advanced medical tourism also significantly contribute to its leadership in providing state-of-the-art stomach cancer treatment.

Recent Developments

• In October 2025, the Abu Dhabi Stem Cells Center (ADSCC) achieved a significant research milestone in cancer treatment by successfully isolating Tumor-Infiltrating Lymphocytes (TILs) from tumor samples for the first time in the UAE. This pioneering achievement marked the launch of the UAE's first program dedicated to developing TIL therapy, a highly personalized form of immunotherapy. While initially demonstrated with breast and lung cancers, this breakthrough in local research held substantial promise for advancing personalized cancer care more broadly, influencing future treatment modalities within the UAE Stomach Cancer Treatment Market by offering new therapeutic avenues.
• In June 2025, groundbreaking Phase II clinical trial results were published for Satricabtagene Autoleucel, a novel CAR-T cell immunotherapy showing remarkable efficacy against advanced stomach cancer. The therapy, designed to genetically modify a patient's immune cells to target cancer, demonstrated significant improvements in tumor shrinkage and overall survival rates for patients with limited treatment options. Such global advancements in innovative cancer treatments directly influence the UAE Stomach Cancer Treatment Market, as the region actively seeks and adopts cutting-edge therapies and medical technologies to provide improved outcomes for its patients.
• In May 2025, Insilico Medicine, an artificial intelligence-driven drug discovery company, announced a pilot project in the United Arab Emirates aimed at discovering a novel drug candidate for oncology therapeutics. The entire process, from target identification to preclinical nomination, was planned to be conducted locally. This ambitious initiative, focusing on genetically validated synthetic-lethality targets for solid tumors, including stomach cancer, represented a significant breakthrough in pharmaceutical research within the UAE. It demonstrated the country's growing capacity for developing innovative treatments, directly impacting the future landscape of the UAE Stomach Cancer Treatment Market.
• In August 2024, Thumbay Healthcare, a prominent private academic healthcare network in the UAE, inaugurated its new Thumbay Advanced Cancer Center. Located within Thumbay University Hospital in Ajman, this state-of-the-art facility expanded regional cancer care capabilities. The center launched specialized services, including a dedicated stomach/gastric cancer screening package. This initiative bolstered the UAE Stomach Cancer Treatment Market by enhancing access to early diagnostic tools and comprehensive oncology consultations, reflecting the group's commitment to advancing cancer detection and treatment options for patients across the region.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Viatris Inc.
• Roche Holding AG
• Eli Lilly and Company
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Celltrion Healthcare
• Samsung Bioepis

By Treatment Type	By Disease Indication	By Route Of Administration	By Drug Class	By Region
Standard Chemotherapy Targeted Therapy and Immunotherapy	Gastric cancer/Gastroesophageal Junction cancer Gastrointestinal Stromal Tumours	Oral and Injectable	PD-1/PD-L1 Inhibitors HER2 Antagonists VEGFR Antagonists and Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Stomach Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Stomach Cancer Treatment Market, By Treatment Type:

• Standard Chemotherapy
• Targeted Therapy
• and Immunotherapy

• UAE Stomach Cancer Treatment Market, By Disease Indication:

• Gastric cancer/Gastroesophageal Junction cancer
• Gastrointestinal Stromal Tumours

• UAE Stomach Cancer Treatment Market, By Route Of Administration:

• Oral and Injectable

• UAE Stomach Cancer Treatment Market, By Drug Class:

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR Antagonists
• and Others

• UAE Stomach Cancer Treatment Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE